IMAB|I-Mab|Price:4.630|

More Details of I-Mab Company

Novabridge Biosciences is a global biotechnology platform company. The Company combines deep business development expertise with agile translational clinical development to identify, accelerate, and advance breakthrough assets. Its differentiated pipeline includes givastomig, a bispecific antibody (Claudin 18.2 x 4-1BB), and VIS-101, a bifunctional biologic, targeting VEGF-A and ANG2. Givastomig conditionally activates T cells via the 4-1BB signaling pathway in the tumor microenvironment where Claudin 18.2 is expressed. Givastomig is being developed to treat Claudin 18.2-positive gastric cancer and other gastrointestinal malignancies. VIS-101 targets VEGF-A and ANG-2 to provide more potent and durable treatment benefits for patients with wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). VIS-101 is completing a large, randomized, dose-ranging Phase 2 study for wet AMD.

I-Mab Info



Ticker SymbolIMAB

Company nameNovaBridge Biosciences

IPO dateJan 17, 2020

CEOFu (Xi-Yong)

Number of employees32

Security typeDepository Receipt

Fiscal year-endJan 17

AddressSuite 400, 2440 Research Blvd

CityROCKVILLE

Stock exchangeNASDAQ Global Market Consolidated

CountryUnited States of America

Postal code20850

Phone13016702800

Websitehttp://www.novabridge.com/#/

Ticker SymbolIMAB

IPO dateJan 17, 2020

CEOFu (Xi-Yong)

Company Executives of I-Mab



Name

Name/Position

Position

Shareholding

Change

Mr. Wei Fu

Executive Chairman of the Board

--

Mr. Chun Kwok (Alan) Au

Independent Director

--

Mr. Chia-Hung (Conor) Yang

Independent Director

--

Dr. Phillip Dennis, M.D., Ph.D.

Chief Medical Officer

--

Dr. Xi-Yong (Sean) Fu, Ph.D.

Chief Executive Officer, Director

--

Dr. Robert Lenz, M.D., Ph.D.

Independent Director

--

,

Independent Director

--

,

Chief Business Development Officer, Director

--

Mr. Kyler Lei

Chief Financial Officer

--

Mr. Claire Xu

Senior Vice President - Clinical Development

--

Name

Name/Position

Position

Shareholding

Change

Mr. Wei Fu

Executive Chairman of the Board

--

Mr. Chun Kwok (Alan) Au

Independent Director

--

Mr. Chia-Hung (Conor) Yang

Independent Director

--

Dr. Phillip Dennis, M.D., Ph.D.

Chief Medical Officer

--

Dr. Xi-Yong (Sean) Fu, Ph.D.

Chief Executive Officer, Director

--

Dr. Robert Lenz, M.D., Ph.D.

Independent Director

--

Revenue Breakdown

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

FY2018

Relevant data have not been disclosed by the company yet.

By RegionUSD

Name

Revenue

Proportion

China (Mainland)

0.00

0.00%

By Business

By Region

Relevant data have not been disclosed by the company yet.

Shareholding Stats

Updated: Fri, Feb 6

Shareholders

Shareholder Types

Shareholders

Proportion

Everest Medicines Ltd

13.74%

CBC Group

11.48%

T Investment Ltd

7.09%

Janus Henderson Investors

6.93%

HHLR Advisors, Ltd.

5.19%

Other

55.57%

Shareholders

Proportion

Everest Medicines Ltd

13.74%

CBC Group

11.48%

T Investment Ltd

7.09%

Janus Henderson Investors

6.93%

HHLR Advisors, Ltd.

5.19%

Other

55.57%

Shareholder Types

Shareholders

Proportion

Corporation

20.83%

Investment Advisor/Hedge Fund

14.74%

Private Equity

11.48%

Hedge Fund

7.32%

Investment Advisor

3.81%

Research Firm

2.06%

Individual Investor

0.56%

Venture Capital

0.26%

Sovereign Wealth Fund

0.06%

Other

38.88%

Institutional Shareholding



Updated: Thu, Jan 1

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q4

110

43.66M

37.89%

+7.89M

2025Q3

108

25.11M

21.79%

-19.02M

2025Q2

118

35.60M

36.28%

-16.36M

2025Q1

125

33.28M

40.75%

-18.83M

2024Q4

137

31.58M

39.04%

-19.85M

2024Q3

150

39.14M

48.39%

-19.95M

2024Q2

195

40.08M

49.56%

-22.86M

2024Q1

267

37.63M

46.01%

-10.84M

2023Q4

298

37.94M

46.39%

-12.75M

2023Q3

330

40.42M

49.01%

-6.90M

Shareholder Activity



Name

Shares Held

Proportion

Change

Chg %

Date

Everest Medicines Ltd

15.85M

13.74%

+15.85M

--

Aug 05, 2025

CBC Group

11.95M

10.37%

-2.64M

-18.11%

Aug 05, 2025

T Investment Ltd

8.17M

7.09%

--

Mar 19, 2025

Janus Henderson Investors

7.99M

6.93%

+7.99M

--

Sep 30, 2025

HHLR Advisors, Ltd.

5.98M

5.19%

--

Sep 30, 2025

Adage Capital Management, L.P.

3.34M

2.9%

+3.34M

--

Sep 30, 2025

Candriam Luxembourg S.A.

1.61M

1.4%

+2.26K

+0.14%

Nov 30, 2025

Exome Asset Management LLC

1.44M

1.25%

+1.44M

--

Sep 30, 2025

Ariose Capital Management Limited

1.70M

1.48%

+1.61M

+1667.03%

Sep 30, 2025

Morgan Stanley & Co. LLC

1.36M

1.18%

+1.30M

+2235.39%

Sep 30, 2025

Related ETFs



Updated: Sat, Dec 6

Name

Proportion

ALPS Barron's 400 ETF

0.3%

SPDR S&P Emerging Markets Small Cap ETF

0.04%

SPDR S&P China ETF

0.01%

SPDR Portfolio Emerging Markets ETF

0.01%

ActivePassive International Equity ETF

0%

Invesco Golden Dragon China ETF

0%

SPDR S&P Emerging Asia Pacific ETF

0%

Avantis Emerging Markets Small Cap Equity ETF

0%

Invesco NASDAQ Future Gen 200 ETF

0%

ALPS Barron's 400 ETF

Proportion0.3%

SPDR S&P Emerging Markets Small Cap ETF

Proportion0.04%

SPDR S&P China ETF

Proportion0.01%

SPDR Portfolio Emerging Markets ETF

Proportion0.01%

ActivePassive International Equity ETF

Proportion0%

Invesco Golden Dragon China ETF

Proportion0%

SPDR S&P Emerging Asia Pacific ETF

Proportion0%

Avantis Emerging Markets Small Cap Equity ETF

Proportion0%

Invesco NASDAQ Future Gen 200 ETF

Proportion0%

Dividend



A total of 0.00 USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

No Data

Stock Splits



Date

Ex-dividend Date

Type

Ratio

No Data

Date

Ex-dividend Date

Type

Ratio

No Data